Labcorp (NYSE: LH) EVP Megan Bailey reports RSU vesting and tax share withholding

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Megan D. Bailey reported equity compensation activity involving restricted stock units and common shares. On February 11, 2026, 403 restricted stock units were converted into 403 shares of common stock, increasing her directly held common shares to 4,286. To cover tax withholding obligations, 138 common shares were withheld at a price of $289.89 per share, leaving her with 4,148 directly owned common shares. Following these transactions, she also directly holds 2,827 restricted stock units that vest in three equal annual installments beginning on February 11, 2026.

Insider Trade Summary

403 shares exercised/converted

Mixed 3 txns

Insider Bailey Megan D.

Role EVP, Pres, Central Labs & Intl

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	403	$0.00	--
Exercise	Common Stock	403	$0.00	--
Tax Withholding	Common Stock	138	$289.89	$40K

Holdings After Transaction: Restricted Stock Unit — 2,827 shares (Direct); Common Stock — 4,286 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Stock withholding to satisfy tax withholding obligations. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Megan D.

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Pres, Central Labs & Intl

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		M		403	A	(1)	4,286	D
Common Stock	02/11/2026		F(2)		138	D	$289.89	4,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/11/2026		M			403	(3)	(3)	Common Stock	403	$0	2,827(4)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Megan D. Bailey	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Labcorp (LH) executive Megan D. Bailey report?

Megan D. Bailey reported the conversion of 403 restricted stock units into 403 Labcorp common shares, plus a withholding of 138 shares to cover taxes. After these moves, she directly owns 4,148 common shares and 2,827 restricted stock units.

How many Labcorp (LH) shares does Megan D. Bailey own after the Form 4?

After the reported transactions, Megan D. Bailey directly owns 4,148 Labcorp common shares. She also holds 2,827 restricted stock units, each representing the right to receive one share of common stock, subject to vesting conditions over time.

What was the purpose of the 138 Labcorp (LH) shares disposed of on February 11, 2026?

The 138 Labcorp shares were withheld to satisfy tax withholding obligations tied to the vesting and conversion of restricted stock units. This disposition, coded “F”, represents a tax-related share withholding rather than an open-market sale of common stock.

How do the restricted stock units reported by Megan D. Bailey in Labcorp (LH) vest?

The restricted stock units reported by Megan D. Bailey vest in three equal annual installments beginning on February 11, 2026. Each unit represents the contingent right to receive one share of Labcorp common stock when the vesting conditions are satisfied.

What transaction codes appear in Megan D. Bailey’s Labcorp (LH) Form 4?

The Form 4 shows transaction code “M” for the exercise or conversion of 403 restricted stock units into common shares and code “F” for the tax withholding disposition of 138 common shares. Both transactions involve directly held equity awards and compensation-related activity.

What position does Megan D. Bailey hold at Labcorp (LH) in this Form 4 filing?

In this Form 4, Megan D. Bailey is listed as an officer of Labcorp, serving as Executive Vice President and President, Central Labs & International. The reported transactions reflect changes in her directly held equity compensation and common share ownership.